Istituto Gentili has enriched its portfolio with ondansetron (antiemetic antiserotoninergic), indicated for nausea and vomiting due to chemotherapy (CINV), radiotherapy (RINV) and surgery (PONV).
If left untreated, CINV can affect between 60% and 80% of cancer patients. Inadequate control of nausea and vomiting can reduce a patient's quality of life and increase the cost of health care. Still, the biggest problem with issues such as CINV and RINV is that they often prevent patients from completing treatment, resulting inup to 50% of patients delaying or refusing possible life-saving cancer therapy.